Loading...

MediWound Ltd.

MDWD•NASDAQ
HealthcareBiotechnology
$20.87
$0.36(1.76%)

MediWound Ltd. (MDWD) Stock Overview

Explore MediWound Ltd.’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
8.22%
↑ 8.22%
Profit Growth
$-2.80
↓ 350.03%
EPS Growth
$-2.80
↓ 304.00%
Operating Margin
-95.94%
↓ 26.88%
ROE
-113.56%
↓ 350.03%
Dividend Yield
0.00%

Analyst Recommendations

Strong Buy
0
Buy
2
Hold
0
Sell
0
Strong Sell
0

Price Targets

Low$28.00
Average$34.33
High$39.00

Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

CEO

Mr. Ofer Gonen B.Sc.

Employees

111

Headquarters

42 Hayarkon Street, Yavne

Founded

2014

Frequently Asked Questions

Meyka LogoMeyka

Meyka is the best Alternative Data platform powered by AI providing research insights for investors

Connect With Us

Legal

Resources

Market

Legal Disclaimer

The information provided by Meyka AI PTY LTD is for informational and research purposes only and does not constitute financial, investment, or trading advice. Meyka is a research platform, not a financial advisory service. Investing in financial markets involves risks, and past performance does not guarantee future results. Users should conduct their own due diligence, consult with professional financial advisors, and assess their risk tolerance before making investment decisions. Meyka and its operators are not liable for any financial losses incurred from the use of information on this platform. The data provided is derived from publicly available sources and is believed to be reliable but may not always be accurate or up to date. Users should independently verify information and not rely solely on Meyka for financial decisions. By using Meyka, you acknowledge that it does not provide financial advice or recommendations and agree to seek guidance from a qualified financial professional before making any investment decisions.

© 2025 Meyka AI PTY LTD. All rights reserved.